Target: ADSL (Adenylosuccinate Lyase)
Gene ID: 158 (NCBI)
UniProt ID: P30566
Function: Catalyzes two reactions in de novo purine synthesis:
Structure: 55 kDa protein with enzymatic activity dependent on fumarate production
Breast Cancer:
Prostate Cancer:
ADSL deficiency causes:
| Supplier | Catalog # | Clonality | Applications |
|---|---|---|---|
| Proteintech | 15264-1-AP | Polyclonal | WB, IHC, IF/ICC, FC |
| Atlas Antibodies | HPA000525 | Polyclonal | WB, ICC, IHC |
| Novus Biologicals | NBP1-87406 | Polyclonal | WB, ICC, IHC |
Perform siRNA-mediated ADSL knockdown with rescue experiments using siRNA-resistant ADSL constructs to confirm target specificity .
Include species-specific positive controls (human, mouse, rat) and compare observed molecular weight (55 kDa) against calculated mass (54.9 kDa) .
Validate using peptide-blocking assays with the immunogen (ADSL fusion protein Ag7332) .
Store at -20°C in PBS with 50% glycerol and 0.02% sodium azide .
Avoid repeated freeze-thaw cycles; aliquot into single-use volumes for high-throughput experiments .
Knockout controls: Use ADSL-depleted cell lysates (e.g., siRNA-treated LNCaP/C4-2B cells) .
Isotype controls: Rabbit IgG for polyclonal antibody validation .
ADSL silencing increases 53BP1 foci formation (≥5 foci/cell) by 3.8-fold, indicating DNA damage accumulation .
Combine with ATM inhibitors (e.g., KU5593) to differentiate replication stress from direct DNA damage .
Monitor RPA2 nuclear intensity as a marker of replication stress .
Flow cytometry: ADSL knockdown increases G1-phase cells by 22% (p<0.05) via p53/p21 activation .
Co-staining: Ki67 (proliferation) with p53 (cell cycle arrest) in ADSL-depleted RPE-1 cells .
Rescue experiments: Express siRNA-resistant ADSL* to restore Ki67 positivity .
| Method | Key Parameters |
|---|---|
| siRNA knockdown | Use siRNA 1 (CCAGUUUCCUGCAGCUCUUTT) |
| Xenograft models | Monitor tumor growth in ADSL-silenced C4-2B |
| Pathway analysis | Assess CDK4, CDC2, and Bcl2 expression |
Zebrafish embryos: Show neuroectodermal defects with ADSL morpholino knockdown .
Chicken embryos: Display reduced retinal proliferation (Ki67-negative cells) .
Human RPE-1 cells: Quantify differentiation markers (vimentin/CK20) post-silencing .
Map antibody epitopes using truncated recombinant proteins (e.g., AA 1-310 vs. 185-280) .
Compare reactivity across species (human vs. dog/guinea pig) using cross-species WB .
For co-staining with cell cycle markers, use sequential immunofluorescence with 0.1% Triton-X permeabilization .
In proliferation assays, combine Trypan Blue exclusion with β-galactosidase staining to distinguish quiescence from senescence .
For clinical correlations, analyze ADSL expression in TCGA prostate adenocarcinoma datasets alongside cell cycle pathway genes .